Oncology Target Discovery by RNAi: The past, present, and future perspectives By Dr Hakim Djaballah and Bhavneet Bhinder Despite an investment of billions of US dollars in the search of novel therapies, cancer still remains the leading cause of death in the world. This emphasises the need to identify novel… Read More
New Tools Bring Greater Understanding to Cellular Metabolism Research By Dr John Comley The links between mitochondrial dysfunction and various diseases and pathological conditions are being increasingly revealed, such that mitochondrial analyses have gained renewed interest from both the academic research and drug discovery labs. This revival of interest in… Read More
The CRISPR/Cas9 System: Cutting a path for rapid generation of more translational animal models. By Dr Kevin M. Gamber The recent high-profile translational failures in mouse models have highlighted the need for more relevant animal models. Advances in gene editing tools, including the CRISPR/Cas9 system, have enabled the modification of… Read More
Automating The Drive Towards Personalised Medicine By Dr Alexandre Akoulitchev, Dr Howard Womersley and Dr Phil Jordan Interest in personalised medicine continues to grow, and epigenetic biomarkers are very informative in this respect, giving a clear indication of whether (and how) a patient’s gene expression profile has changed, as well… Read More
Library Logistics: Managing Comprehensive Compound Collections By Dr Jorg Kroll and David Booth Compound management may seem straightforward but in reality, as the number of new compounds increases dramatically year-on-year, the management of large collections has become increasingly challenging. As highthroughput technologies have become the norm, Bayer HealthCare, a global… Read More
Could The Keys To Precision & Personalised Medicine Be Rooted In Predictive Safety & Research Methods? By Robert G. Hunter To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care. Although a high… Read More
Long Live Peptides - Evolution of peptide half-life extension technologies and emerging hybrid approaches By Dr Ronald V. Swanson Among therapeutic modalities, peptides occupy a middle ground between traditional ‘small molecule’ drugs and the larger injectable biologics, not fitting comfortably into either category. Peptides, particularly those based on endogenous human… Read More
Collaboration For Innovation Is The New Mantra For The Pharmaceutical Industry By Professor Jackie Hunter In order to maintain a flow of innovative medicines there is a growing realisation that companies cannot allow the status quo to remain as it is and the need to identify sources of appropriate knowledge… Read More
Digital PCR (dPCR) and Real-Time PCR (qPCR): A time and place for each By Dr George Karlin-Neumann and Dr Rachel Scott When it comes to DNA research, scientists often find themselves weighing digital PCR (dPCR) against the more established quantitative real-time PCR (qPCR). Which technique is better to use? The… Read More
By Dr John Comley 3D cell culture has the potential to deliver higher quality culture information that is more representative of tissue morphology and predictive of drug responses in vivo. Three years ago we concluded in DDW that 3D cell culture was still open to major improvements, so what has… Read More
Stem Cell Banking In Support of Drug Discovery By Dr Thomas J Novak, Dr Uta Grieshammer, Dr Michael Yaffe and Dr Steve Madore The discovery by Yamanaka and Thomson in 2007 that human somatic cells can be reprogrammed to a pluripotent state (ie, induced pluripotent stem cells, iPSCs) has revolutionised… Read More
Large-Scale Expansion of Stem Cells For Therapy and Screening By Dr Y. John Shyu, Dr Katherine E. Strathearn and Dr Richard M. Eglen Recently, pre-clinical and clinical studies of stem cells in regenerative medicine have demonstrated great promise as treatments for various diseases. Their ability to self-renew and differentiate makes… Read More
Exploring The Feasibility of Human Antimicrobial Peptides For New and More Efficient Antibiotics By Dr Max Ryadnov To help combat decades of stagnation in antibiotic development, a team led by the National Physical Laboratory conducted two studies into the antimicrobial peptides that fight infection in our bodies and the feasibility… Read More
Biomarker Discovery: The Need For New Generation Peptide-Protein Microarrays By Dr Nikolai Schwabe and Katherine Catchpole The progression from health to disease is marked by significant biological changes within an individual (1). Clinically presenting symptoms, however, can be non-specific and variable enough to hinder diagnosis, and may appear only after… Read More
Fluorescence Lifetime Assays By Dr Graham Cotton, Dr Wayne Bowen, Dr Robert Grundy and Dr Ulrich Hassiepen The benefits of fluorescence lifetime-based technologies (FLT) have been highlighted for more than a decade but thus far they have failed to gain widespread acceptance. Significant improvements in assay reagents and availability of… Read More
By Dr Alejandra Solache, Robert Brockett, Trinette Chuang, Dr Robin Clark, Rey Dimagiba, Dr April Fisher, Dr Wayne Speckmann and Dr Chun Yang Antibodies have become a vital tool among researchers in the life sciences and are routinely being used in a number of diverse immunoassay applications, including Western blotting… Read More